Linsitinib (BioDeep_00000180492)
human metabolite blood metabolite
代谢物信息卡片
化学式: C26H23N5O (421.1903)
中文名称: Linsitinib
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O
InChI: InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:91402
- PubChem: 11640390
- HMDB: HMDB0254107
- DrugBank: DB06075
- ChEMBL: CHEMBL1996234
- ChEMBL: CHEMBL1091644
- Wikipedia: Linsitinib
- chemspider: 9815131
- CAS: 1356958-77-4
- CAS: 867160-71-2
- CAS: 867160-72-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
亚细胞结构定位 | 关联基因列表 |
---|
文献列表
- Heng Wang, Jing Bi, Yuan Zhang, Miaomiao Pan, Qinglong Guo, Genhui Xiao, Yumeng Cui, Song Hu, Chi Kin Chan, Ying Yuan, Takushi Kaneko, Guoliang Zhang, Shawn Chen. Human Kinase IGF1R/IR Inhibitor Linsitinib Controls the In Vitro and Intracellular Growth of Mycobacterium tuberculosis.
ACS infectious diseases.
2022 10; 8(10):2019-2027. doi:
10.1021/acsinfecdis.2c00278
. [PMID: 36048501] - Fangyuan Chen, Qingya Shi, Fen Pei, Andreas Vogt, Rebecca A Porritt, Gustavo Garcia, Angela C Gomez, Mary Hongying Cheng, Mark E Schurdak, Bing Liu, Stephen Y Chan, Vaithilingaraja Arumugaswami, Andrew M Stern, D Lansing Taylor, Moshe Arditi, Ivet Bahar. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Molecular systems biology.
2021 08; 17(8):e10239. doi:
10.15252/msb.202110239
. [PMID: 34339582] - Daniel N Meijles, Stephen J Fuller, Joshua J Cull, Hajed O Alharbi, Susanna T E Cooper, Peter H Sugden, Angela Clerk. The insulin receptor family and protein kinase B (Akt) are activated in the heart by alkaline pH and α1-adrenergic receptors.
The Biochemical journal.
2021 06; 478(11):2059-2079. doi:
10.1042/bcj20210144
. [PMID: 34002209] - Margaret von Mehren, Suzanne George, Michael C Heinrich, Scott M Schuetze, Jeffrey T Yap, Jain Q Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A Janeway, Jason L Hornick, Douglas B Flieder, Rashmi Chugh, Lori Rink, Annick D Van den Abbeele. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 04; 26(8):1837-1845. doi:
10.1158/1078-0432.ccr-19-1069
. [PMID: 31792037] - Jun Shirakawa, Kazuki Tajima, Tomoko Okuyama, Mayu Kyohara, Yu Togashi, Dario F De Jesus, Giorgio Basile, Tatsuya Kin, A M James Shapiro, Rohit N Kulkarni, Yasuo Terauchi. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.
Diabetologia.
2020 03; 63(3):577-587. doi:
10.1007/s00125-019-05071-w
. [PMID: 31897526] - Pedro Barata, Matthew Cooney, Allison Tyler, John Wright, Robert Dreicer, Jorge A Garcia. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Investigational new drugs.
2018 06; 36(3):451-457. doi:
10.1007/s10637-018-0574-0
. [PMID: 29476383] - Robert F Place, Christine C Krieger, Susanne Neumann, Marvin C Gershengorn. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.
British journal of pharmacology.
2017 02; 174(4):328-340. doi:
10.1111/bph.13693
. [PMID: 27987211] - Srinivasu Poondru, Jorge Chaves, Geoffrey Yuen, Barbara Parker, Elizabeth Conklin, Margaret Singh, Masanori Nagata, Stanley Gill. Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
Cancer chemotherapy and pharmacology.
2016 Apr; 77(4):829-37. doi:
10.1007/s00280-016-2999-5
. [PMID: 26972330] - Roger Ramcharan, Tamara Aleksic, Wilfride Petnga Kamdoum, Shan Gao, Sophia X Pfister, Jordan Tanner, Esther Bridges, Ruth Asher, Amanda J Watson, Geoffrey P Margison, Mick Woodcock, Emmanouela Repapi, Ji-Liang Li, Mark R Middleton, Valentine M Macaulay. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Oncotarget.
2015 Nov; 6(37):39877-90. doi:
10.18632/oncotarget.5631
. [PMID: 26497996] - Igor Puzanov, Colin R Lindsay, Laura Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T R Jeffry Evans. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015 Feb; 21(4):701-11. doi:
10.1158/1078-0432.ccr-14-0303
. [PMID: 25212606] - Robin L Jones, Edward S Kim, Pilar Nava-Parada, Salma Alam, Faye M Johnson, Andrew W Stephens, Ronit Simantov, Srinivasu Poondru, Rich Gedrich, Scott M Lippman, Stan B Kaye, Craig P Carden. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015 Feb; 21(4):693-700. doi:
10.1158/1078-0432.ccr-14-0265
. [PMID: 25208878] - Ling Xu, Xiujuan Qu, Xuejun Hu, Zhitu Zhu, Ce Li, Enze Li, Yanju Ma, Na Song, Yunpeng Liu. Lipid raft-regulated IGF-1R activation antagonizes TRAIL-induced apoptosis in gastric cancer cells.
FEBS letters.
2013 Nov; 587(23):3815-23. doi:
10.1016/j.febslet.2013.10.007
. [PMID: 24161672] - Filip Janku, Helen J Huang, Laura S Angelo, Razelle Kurzrock. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.
Oncotarget.
2013 Mar; 4(3):463-73. doi:
10.18632/oncotarget.886
. [PMID: 23531874]